查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869813

腎臟病市場規模、佔有率和趨勢分析報告：按檢測類型、應用、最終用途、地區和細分市場預測（2025-2033 年）

Preeclampsia Market Size, Share & Trends Analysis Report By Test Type (Blood Test, Urinalysis), By Application Universal Screening, Targeted Testing, By End Use (Hospitals, Diagnostic Centers), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

腎臟病市場摘要

預計到 2024 年，全球腎臟病前症市場規模將達到 12.5 億美元，到 2033 年將達到 27.3 億美元。

預計從 2025 年到 2033 年，該市場將以 9.12% 的複合年成長率成長。推動市場成長的因素包括腎臟病率的上升，以及對早期、準確的診斷測試的需求不斷成長，以便在病情惡化之前預測和管理風險。

全球每年約有1.4億新生兒出生，光是美國每年就有約370萬名新生兒出生。高達30%的妊娠會受到併發症的影響，包括早產、腎臟病前症和胎兒生長受限。 2025年4月，Mirvie宣布其簡單的血液檢測可以預測妊娠17.5至22週時發生腎臟病的風險，使臨床醫生能夠對患者進行風險分層並儘早干預。腎臟病是一種妊娠高血壓，影響全球約2%至8%的懷孕。它通常在懷孕20週後發生，診斷依據是器官功能障礙的徵兆，例如高血壓和蛋白尿。如果未能及時發現或治療，子癇前症可能發展為子癇（抽搐）、HELLP症候群、胎盤早期剝離和其他嚴重併發症。據估計，腎臟病每年在全球造成約46,000例孕產婦死亡和500,000例胎兒及新生兒死亡。由於子癇前症是導致孕產婦和周產期發病率的重要因素，因此迫切需要更好的預防、診斷和治療手段。

腎臟病是一種嚴重的高血壓，在美國，大約每12至25例妊娠中就有1例發生子癇前期，且發生率呈上升趨勢。診斷子癇前症需要滿足妊娠20週後血壓升高，並伴隨器官損傷的指標，例如尿蛋白（提示腎臟損傷）。風險因素包括腎臟病病史、先前慢性糖尿病或高血壓、初產。

近年來，珀金埃爾默等公司已將DELFIA Xpress sFlt-1試劑盒納入其獲得CE-IVD認證的妊娠高血壓診斷產品組合。賽默飛世爾科技的BRAHMS生物標記檢測（sFlt-1/PlGF）目前可用於妊娠高血壓的檢查室管理，提供精確的風險評估。隨著無細胞RNA檢測（Mirvie）和預測風險評分等新型分子檢測技術的成熟和獲得監管部門核准，市場有望拓展至更早期的產前護理領域。此外，人們對孕產婦健康的日益關注、新興國家意識的提高以及對女性健康科技投資的不斷增加，也進一步推動了全球市場的成長。

然而，這些技術的普及程度並不均衡。儘管需求龐大，但由於缺乏生物標記檢測的基礎設施、資金限制以及產前保健方面的差異，先進檢測技術在資源匱乏地區並未廣泛應用。世界衛生組織指出，現有指引的實施進展緩慢，硫酸鎂在許多資源匱乏地區仍未充分利用。此外，在許多地區，新型診斷技術的市場滲透受到監管和報銷障礙的限制。然而，隨著成本的降低和檢測方式（例如，照護現場和居家檢體採集）的日益便捷，這些障礙有望得到緩解。

目錄

第1章腎臟病市場：調查方法與範圍

2.腎臟病市場：執行摘要

  • 市場概述
  • 測試類型和應用程式簡介
  • 最終用途簡介
  • 競爭格局概覽

3.腎臟病市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章腎臟病市場：檢測類型估算與趨勢分析

  • 腎臟病市場：檢測類型差異分析
  • 血液檢查
  • 尿液檢查

第5章腎臟病市場：應用預測與趨勢分析

  • 腎臟病市場：應用變化分析
  • 一般篩檢
  • 針對性檢測
  • 監測和復發監測

6.腎臟病市場：終端用戶需求預測及趨勢分析

  • 腎臟病市場：終端用途差異分析
  • 醫院
  • 專科診所
  • 診斷中心
  • 其他

7.腎臟病市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭情勢

  • 公司分類
  • 策略規劃
    • 推出一種新的測試類型
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市佔率分析，2024 年
  • 公司熱力圖分析
  • 公司簡介
    • Thermo Fisher Scientific
    • Revvity
    • Diabetomics, Inc.
    • F. Hoffmann-La Roche
    • Metabolomic Diagnostics Ltd.（Trinity Biotech）
    • Sera Prognostics
    • Siemens Healthineers AG
    • Bayer AG
    • Quidel Corp
    • EUROFINS NTD GENETICS
    • LABCORP
    • MPROBE'S
Product Code: GVR-4-68040-772-8

Preeclampsia Market Summary

The global preeclampsia market size was valued at USD 1.25 billion in 2024 and is expected to reach USD 2.73 billion by 2033, growing at a CAGR of 9.12% from 2025 to 2033. The market is driven by rising incidences of the preeclampsia and the rising demand for early and accurate diagnostic tests to predict and manage risks before symptoms grow.

Globally, there are near about 140 million births annually; in the U.S. alone, about 3.7 million births per year, of which up to 30 % of pregnancies are affected by complications (including preterm birth, preeclampsia, restricted growth, etc.). In April 2025, Mirvie highlighted that its simple blood test can predict preeclampsia risk in pregnancy as early as 17.5 to 22 weeks-helping clinicians stratify patients and intervene sooner. Preeclampsia is a hypertensive disorder of pregnancy that affects roughly 2 % to 8 % of pregnancies worldwide. It typically presents after 20 weeks of gestation, and is diagnosed by elevated blood pressure and signs of organ dysfunction such as proteinuria. If undetected or unmanaged, the condition can progress to eclampsia (seizures), HELLP syndrome, placental abruption, or other severe complications. Each year, preeclampsia is estimated to be responsible for about 46,000 maternal deaths and 500,000 fetal or newborn deaths globally. Because it contributes significantly to maternal and perinatal morbidity, there is strong demand for better preventive, diagnostic, and management tools.

Preeclampsia is a serious blood pressure condition in the U.S. that affects about 1 in 12 to 1 in 25 pregnancies and is on the rise. After 20 weeks of pregnancy, high blood pressure and indicators of organ damage, such as protein in the urine, which suggests kidney damage, are necessary for the diagnosis. A history of preeclampsia, pre-existing chronic diabetes or hypertension, and first-time pregnancy are risk factors.

In the recent year's companies such as PerkinElmer added DELFIA Xpress sFlt-1 kit to its CE-IVD pre-eclampsia product offerings. The Thermo Fisher BRAHMS biomarker assays (sFlt-1 / PlGF) are now marketed for preeclampsia management in labs, offering precise risk calculations. As new molecular tests, such as cell-free RNA assays (Mirvie) or predictive risk scores, mature and get regulatory approval, they will broaden the market's reach into earlier prenatal screening. The global market's growth is further supported by rising maternal health focus, growing awareness in emerging economies, and increased investment in women's health technologies.

Adoption is uneven, though. Despite their great need, advanced tests are not widely adopted in low-resource settings due to a lack of infrastructure for biomarker assays, financial limitations, and gaps in prenatal care. The WHO notes that even with guidelines, implementation lags and magnesium sulfate is still underutilized in many low-resource settings. Furthermore, in many areas, market penetration for novel diagnostics is slowed by regulatory and reimbursement barriers. However, these obstacles might lessen as costs come down and test formats (like point-of-care or home sampling) get easier.

Global Preeclampsia Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preeclampsia market based on test type, application, end use, and region:

  • Test Type Outlook (USD Million; 2021 - 2033)
  • Blood Tests
  • Urinalysis
  • Application Outlook (USD Million; 2021 - 2033)
  • Universal Screening
  • Targeted Testing
  • Monitoring & Recurrence Surveillance
  • End Use Outlook (USD Million; 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Preeclampsia Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test Type Segment
      • 1.1.1.2. Application Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Preeclampsia Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type and Application Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Preeclampsia Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Market driver analysis
      • 3.5.1.1. Rising incidence of preeclampsia
      • 3.5.1.2. Increasing research and development activities
      • 3.5.1.3. Growth in government Initiatives and Screening Guideline
    • 3.5.2. Market restraint analysis
      • 3.5.2.1. High cost of advanced diagnostics test
  • 3.6. Market Restraint Analysis
  • 3.7. Porter's Five Forces Analysis
  • 3.8. PESTLE Analysis
  • 3.9. Pipeline Analysis

Chapter 4. Preeclampsia Market: Test Type Estimates & Trend Analysis

  • 4.1. Preeclampsia Market: Test Type Movement Analysis
  • 4.2. Blood Tests
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Urinalysis
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Preeclampsia Market: Application Estimates & Trend Analysis

  • 5.1. Preeclampsia Market: Application Movement Analysis
  • 5.2. Universal Screening
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Targeted Testing
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Monitoring & Recurrence Surveillance
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Preeclampsia Market: End Use Estimates & Trend Analysis

  • 6.1. Preeclampsia Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Specialty Clinics
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Diagnostic Centers
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Preeclampsia Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Preeclampsia Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Preeclampsia Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Preeclampsia Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. NEW TEST TYPE LAUNCH
    • 8.2.2. PARTNERSHIPS
    • 8.2.3. ACQUISITION
    • 8.2.4. COLLABORATION
    • 8.2.5. FUNDING
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Test Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Revvity
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Test Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Diabetomics, Inc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Test Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. F. Hoffmann-La Roche
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Test Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Metabolomic Diagnostics Ltd.(Trinity Biotech)
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Test Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sera Prognostics
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Test Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Siemens Healthineers AG
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Test Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bayer AG
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Test Type Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Quidel Corp
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Test Type Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. EUROFINS NTD GENETICS
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Test Type Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. LABCORP
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Test Type Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. MPROBE'S
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Test Type Benchmarking
      • 8.5.12.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Preeclampsia Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 5 Global Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 6 Global Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Preeclampsia Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 9 North America Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 10 North America Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Preeclampsia Market, By Test Type, 2018-2030, (USD Million)
  • Table 15 Canada Preeclampsia Market, By Application, 2018-2030, (USD Million)
  • Table 16 Canada Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 21 Europe Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 25 UK Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 26 UK Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 29 Germany Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 31 France Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 32 France Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 41 Sweden Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 44 Norway Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 47 Denmark Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 49 Asia Pacific Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 54 Japan Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 56 China Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 57 China Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 59 India Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 60 India Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 63 Australia Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 66 Thailand Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 69 South Korea Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 71 Latin America Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Preeclampsia Market, By Country, 2018-2030, (USD Million)
  • Table 81 MEA Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 83 MEA Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 86 South Africa Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Preeclampsia Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Preeclampsia Market, By Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Preeclampsia Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global preeclampsia market- Key market driver analysis
  • Fig. 7 Global preeclampsia market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global preeclampsia market - Porter's analysis
  • Fig. 10 Global preeclampsia market - PESTEL analysis
  • Fig. 11 Global preeclampsia market Test Type outlook key takeaways
  • Fig. 12 Global preeclampsia market: Test Type movement analysis
  • Fig. 13 Blood Tests market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Urinalysis market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Global preeclampsia market application outlook key takeaways
  • Fig. 16 Global preeclampsia market: application movement analysis
  • Fig. 17 Universal screening market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Targeted testing market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Monitoring & recurrence surveillance market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Global preeclampsia market end use outlook key takeaways
  • Fig. 21 Global preeclampsia market: end use movement analysis
  • Fig. 22 Hospitals market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Specialty clinics market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Diagnostic centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Other End-users market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Global Preeclampsia market: Regional movement analysis
  • Fig. 28 North America Preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 33 UK preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 35 France preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 36 Spain preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 38 Denmark preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 39 Sweden preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 41 Asia Pacific preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 42 Japan preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 43 China preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 44 India preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 45 South Korea preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 46 Australia preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 47 Thailand preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 48 Latin America preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 49 Brazil preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 50 Argentina preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 51 MEA preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 52 South Africa preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 53 Saudi Arabia preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 54 UAE preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 55 Kuwait preeclampsia market, 2021 - 2033 (USD Million)
  • Fig. 56 Strategy framework